

CURRICULUM VITAE

Giuseppe Sconocchia, MD
giuseppe.sconocchia@unicamillus.org

Personal data

Citizenship: Italian

Marital status: married

Education:

1996: Specialty in Internal Medicine at University of Rome, Tor Vergata.

1990: Specialty in Hematology (cum Laude) at University of Rome, Tor Vergata

1985: Degree in Medicine (cum Laude), University of Rome, La Sapienza

1977: B.S. (Liceo Scientifico) Morlupo, Rome.

Clinical, Scientific, and Academic Career

1981-1982: Sergeant, Italian Navy

1983-85: undergraduate fellow at the Department of Surgical Pathology, University of Rome, La Sapienza, Italy

1985-86: postgraduate fellow at the Department of Internal Medicine and Cardiology, Civita Castellana Hospital, Italy.

1986-89: Internship Internal Medicine, Civita Castellana and Fellowship in Cellular Immunology, Rome, Italy

1989-90: Attending physician at the Department of Surgery, Viterbo Hospital (incaricato)

1990-91: Attending physician (permanent position) at the Department of Internal Medicine, Civita Castellana Hospital, Italy.

1991-2007 Investigator (i/e Assistant Member), CNR Institute for Organ Transplantation and Immunocytology c/o Department of Surgery, School of Medicine, University of Rome, Tor Vergata

2005-2007: Scientific Consultant “Lazio Regional Agency for Organ Transplantation and Related Diseases

2008-2011: Scientific Consultant “Lazio Regional Agency for Organ Transplantation and Related Diseases

2007- First Investigator (i/e Associate Member), CNR, Institute of Translational Pharmacology (ITF), Rome, Italy

2011- Coordinator, CNR, Departmental (Medicine) Project: Immunology and Infectivology

2012: Qualified expert for Cell Factory for Advanced Therapy Laboratories

2013-: Guest Hematologist, Clinical Hematology Myeloproliferative Disease Unit, University of Rome “Tor Vergata”

2016-2020 Acting Director, Institute of Translational Pharmacology, Italian National Research Council, Rome

2022-2023 Acting Director, Institute of Biochemistry and Cell Biology, Naples

2018-National Scientific Habilitation (NSA), Associate Professorship in 06/D3- (Oncology/Hematology/Rheumatology) MED/06 (2018-2027)

2020- Dirigente di Ricerca (i/e Full Member) Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy

International stages, training, and appointments

1992-97: Fellow at Immunotargeting Section (director: Dr. David Segal) National Cancer Institute, Experimental Immunology Branch, NIH, Bethesda, USA

2001-2004: Research Fellow (FTE) at Allogeneic Stem Cell Transplantation Section, (Director Dr. John Barrett) Hematology Branch, National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, MD, USA

2004-2005: Junior Faculty (Affiliate Member i/e Instructor), Department of Immunology (Director Dr. Soldano Ferrone), Roswell Park Cancer Institute, Buffalo, NY, USA

2008: Guest Researcher, Section Oncology Surgery, Institute of Surgical Research and Hospital Management, Department Biomedicine, University of Basel, Basel, Switzerland (Prof. Giulio Cesare Spagnoli)

Teaching

2004-2005: Teaching Immunology, Post-graduate students, Roswell Park Cancer Institute/State New York University (SUNY) at Buffalo, New York State, USA.

2005-2011 Professor on contract of Oncology: course of Oncology-Dermatology, post-graduate students, Specialty in Plastic Surgery, University of Rome, School of Medicine

2005-2008 Professor on contract of Tumor Immunology, post-graduate students “Specialty in General Surgery”, University of Rome “Tor Vergata”, School of Medicine

2005-2007 Professor of Medical Pathophysiology, Post-graduate students, Specialty in Nephrology, University of Rome “Tor Vergata”, School of Medicine

2019- Professor on contract in Rheumatology, Saint Camillus, International Medical University, Rome, Italy (Physiotherapy)

2022- Professor on contract, MED/15, Blood Diseases, Saint Camillus, International Medical University, Rome, Italy.

Awards

Contribution to the Bench to Bedside Award, NIH, Bethesda (2002-2003): Improving allogeneic stem cell transplantation through Alloreactive NK (NK) cells immunotherapy to improve the outcome of allogeneic stem cell transplantation (200.000 \$)

Co-investigator, CNR-ME.PO3.007: Biological mechanisms and immunological factors related to HLA alleles (2007-2009).

Co-investigator, CNR-ME.PO3.009: Histocompatibility and Transplant, pre-neoplastic gene regulation (2005-2007)

Principal Investigator, Pediatric Rainbow Association (Onlus) (2007-2008): LAK cells immunotherapy of pediatric malignancies (20.000 Euros)

Recipient of CNR (Italy) -Swiss National Fond (Switzerland) interchange funding (2008): Clinical significance of inflammatory tumor-associated macrophage (TAMs) infiltrating colorectal carcinoma lesions (18.000 Euros)

Principal Investigator, Agenzia Trapianti Regione Lazio: Identification of prognostic factor and correction of colorectal carcinoma evasion mechanism(s) by NK cells derived from hematopoietic stem cells (20.000 Euros)

Principal Investigator, Nando Perretti Foundation (2009-2011): Role of the innate immunity in the pathogenesis of pediatric malignancies and autoimmune disease (20.000 Euros)

Principal Investigator, Associazione Italiana Ricerca sul Cancro (AIRC), Investigator Grant (IG) 10555 (2010-2013): Clinicopathological role of Fc gamma RIII (CD16) positive population in the pathogenesis of common epithelial malignancies (180.000 Euros)

Principal Investigator, Lazio Regional Agency for Transplantation (2012-2013): Role of

macrophages and myeloid-derived suppressor cells in wound healing (55.105,00 Euros)

Principal Section Investigator, MIUR, Projects of national relevance, PRIN, (2013-2015): Optimization of acute myeloid leukemia treatment by innovative therapeutic strategies (210.239,00 Euros).

Principal Investigator, Italian Association for Cancer Research (AIRC), Investigator Grant (IG) 17120 (2016-2019): Targeting colorectal carcinoma utilizing atypical Fc gamma-CAR-T cells combined with anti-EGFR monoclonal antibodies (205.000 Euros)

Consultant: Qatar University Grant-Collaborative and high impact grant application 2018 (2018-20). Fcγ chimeric receptor T cells and monoclonal antibodies for Glioblastoma Multiforme immunotherapy: in vitro and in vivo studies. (150.000 U.S. dollars)

Principal Section Investigator, Rome's Foundation (2018-2021): Diabetes Mellitus, Regenerative and Reparative Processes, and Improvement of Pancreatic Beta Cell Function: Role of Bone Marrow-Mesenchymal Stem Cells, MicroRNAs, M2 Macrophages, and Myeloid-Derived Suppressor Cells (Convenzione Uni. Tor Vergata-Fondazione Roma) (360.000 Euros of which 75.000 Euros were assigned to my unit).

CNR Short-Term mobility: Awarded but not accomplished CAR-T cell program, Allogeneic Bone Marrow Transplantation, King's College, London, March 2020 (suspended because of COVID19 pandemic)

Principal Investigator, Italian Association for Cancer Research (AIRC), Investigator Grant (IG) 2020-24440 (2021-2025): Targeting head /neck cancer by anti-B7-H3 mAb and CD64-T cells: implication in prognosis and therapy. (425.000 Euros)

Principal Section Investigator: National Operational Program (PON), Ministry of the University and Research (MUR)-EU (2021-2023): Nanotechnologies for Tumor Immunotherapy, TITAN (329.000,79 Euros).

Patents

1) TO2014A 000631. Innate chimeric molecules for immunotherapy.

<https://brevetti.cnr.it/InfoCatalogo.do?nsrif=10312&dip=0>

2) US patent application Massachusetts General Hospital 25820-02 - CNR Reference: 10824 - Our Reference: 51412-005001. CD64 Chimeric Receptor and uses thereof

3) PCT international No.PCT/US22/12815- U.S. Patent Application No.: 63/138,152.

Your Reference: MGH 25820-02; CNR Reference: 10824; Our Reference: 51412-005001 provisional patent application Massachusetts General Hospital - CNR. CD64 Chimeric Receptor and uses thereof (2022)

Research Experience

Cellular and Molecular Immunology

Cancer Immunotherapy]

Monoclonal antibodies production

Membership

American Society of Immunology (AAI)-1999-2004

International Society for Biological Therapy (IBST)-2004

Italian Society of Hematology-2011-

Reviewer: Ad hoc: Journal of Translational Medicine. Official: Gastroenterology, Gut, International Journal of Cancer, Clinical Gastroenterology and Hepatology, Cytotherapy, Surgery

Today, Mechanisms of Aging Development, Journal of Cellular and Molecular Medicine, Experimental and Molecular Pathology, Int J Med Sciences, Pancreata, Journal of Biological Regulators & Hemostatic Agents, Bone Marrow Transplantation, Clinical Cancer Research

Editorial Board Member: Associate Editor: Cancers, Frontiers in Immunology, Frontiers in Oncology. Experimental and Molecular Pathology, Journal of Clinical Immunology

References

1. Sconocchia T, Foßelteder J, **Sconocchia G**, Reinisch A. Langerhans cell histiocytosis: current advances in molecular pathogenesis. Front Immunol. 2023 Oct 26; 14:1275085. doi: 10.3389/fimmu.2023.1275085. eCollection 2023.PMID: 37965340.
2. Canossi A, Aureli A, Del Beato T, Novelli G, Buonomo O, Rossi P, Venditti A, Papola F, **Sconocchia G**. Impact of HLA Class I Antigen, Killer Inhibitory Receptor, and FCGR3A Genotypes on Breast Cancer Susceptibility and Tumor Stage. Curr Mol Med. 2023 Jul 17. doi: 10.2174/1566524023666230717162458. Online ahead of print.PMID: 37461339
3. Aureli A, Marziani B, Venditti A, Sconocchia T, **Sconocchia G**. Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond Cancers (Basel). 2023 Jun 26;15(13):3346. doi: 10.3390/cancers15133346.
4. Tassinari V, La Rosa P, Guida E, Colopi A, Caratelli S, De Paolis F, Gallo A, Cenciarelli C, **Sconocchia G**, Dolci S, Cesarini V. Contribution of A-to-I RNA editing, M6A RNA Methylation, and Alternative Splicing to physiological brain aging and neurodegenerative diseases. Mech. Ageing Dev. 2023 Jun; 212:111807. doi: 10.1016/j.mad.2023.111807. Epub 2023 Apr 5. PMID: 37023929 Review
5. **Sconocchia G**, Lanzilli G, Cesarini V, Silvestris DA, Rezvani K, Arriga R, Caratelli S, Chen K, Dou J, Cenciarelli C, Toietta G, Baldari S, Sconocchia T, De Paolis F, Aureli A, Iezzi G, Irno Consalvo M, Buccisano F, Del Principe MI, Maurillo L, Venditti A, Ottaviani A, Spagnoli GC. Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment. Life Sci Alliance. 2022 Oct 14;5(12): e 202201590. doi:10.26508/lsa.202201590. Print 2022 Dec. PMID: 36241426.
6. Pasqualone G, Buzzatti E, Palmieri R, Savi A, Pascale MR, Borsellino B, Guarnera L, Buccisano F, Voso MT, Maurillo L, **Sconocchia G**, Venditti A, Del Principe MI. Case report: *A Saprochaete clavata (Magnusiomyces clavatus)* severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma. Front Oncol. 2022 Sep 15; 12:970188. doi: 10.3389/fonc.2022.970188. eCollection 2022.PMID: 36185191
7. Palmieri R, Othus M, Cheng GS, Buccisano F, Paterno G, Maurillo L, Del Principe MI, **Sconocchia G**, Venditti A, Walter RB. Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia. Haematologica 2022 1;107(11):2752-2755. doi:10.3324/haematol. 2022.281445.PMID: 35924584
8. Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Cifola I, Caratelli S, **Sconocchia G**,

D'Agnano I, Cenciarelli C: Glioma extracellular vesicles for precision medicine: prognostic and theragnostic application. *Discov Oncol.* 2022 Jun 18;13(1):49. doi: 10.1007/s12672-022-00514-0.PMID: 35716231 Review.

9.Aureli A, Marziani B, Sconocchia T, Del Principe MI, Buzzatti E, Pasqualone G, Venditti A, **Sconocchia G.** Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia. *Cancers* 2021 Dec 13;13(24):6246. doi: 10.3390/cancers 13246246. Review.

10.SconocchiaT, **Sconocchia G.** Regulation of the Immune System in Health and Disease by Members of the Bone Morphogenetic Protein Family. *Front Immunol.* 2021 Dec 2;12:802346. doi: 10.3389/fimmu.2021.802346. eCollection 2021.Review

11. Aricò E, Castiello L, Bracci L, Urbani F, Lombardo F, Bacigalupo I, Ancidoni A, Vanacore N, Falcione A, Reggiani C, Dutti GM, Maglie MG, Papa O, Bartoletti PL, Ozzella G, Bevilacqua N, Nicastrì E, Belardelli F, **Sconocchia G.** Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. *Trials* (2021) Sep 3;22(1):584. doi: 10.1186/s13063-021-05367-6.PMID: 34479601.

12. Coppola A, Capuani B, Pacifici F, Pastore D, Arriga R, Bellia A, Andreadi A, Di Daniele N, Lauro R, Della-Morte D, **Sconocchia G,** Lauro D. Activation of Peripheral Blood Mononuclear Cells and Leptin Secretion: New Potential Role of Interleukin-2 and High Mobility Group Box (HMGB)1. *Int J Mol Sci.* 2021 Jul 26;22(15):7988. doi: 10.3390/ijms22157988.PMID: 34360753.

13 Cenciarelli C, Caratelli, S. Arriga R, Lanzilli G, Ottaviani, Sconocchia T, Spagnoli GC, Venditti A, Iezzi G, Roselli M, Lauro D, Marei HE, **Sconocchia G.** EGFR+ Glioblastoma stem cells targeting by CD16158V-chimeric receptor T cells and cetuximab Vol. 1 (No. 1) (2021) March Research Article, 24 35doi:10.48286/aro.2021.04(**Non ancora indicizzata**)

14. Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, Landoni E, Du H, Savoldo B, Ferrone S, Dotti G, **Sconocchia G.** In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. *Int J Cancer* (2020) Jan 1;146(1):236-247. doi: 10.1002/ijc.32663. Epub 2019 Oct 12. PMID: 31479522.

15. Arriga R, Caratelli S, Lanzilli G, Ottaviani A, Cenciarelli C, Sconocchia T, Spagnoli GC, Iezzi G, Roselli M, Lauro D, Coppola A, Dotti G, Ferrone S, **Sconocchia G.** CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab. *Int J Cancer.* 2020 May 1;146(9):2531-2538. doi: 10.1002/ijc.32618. Epub 2019 Aug 30. PMID: 31396956

16.Marei HE, Althani A, Caceci T, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Roselli M, Caratelli S, Cenciarelli C, **Sconocchia G.** Recent perspective on CAR and Fcγ-CR T cell

immunotherapy for cancers: Preclinical evidence versus clinical outcomes. *Biochem Pharmacol.* 2019 Aug; 166:335-346. doi: 10.1016/j.bcp.2019.06.002. Epub 2019 J6. PMID: 31176617 Review.

17. Tosti N, Cremonesi E, Governa V, Basso C, Kancherla V, Coto-Llerena M, Amicarella F, Weixler B, Däster S, **Sconocchia G**, Majno PE, Christoforidis D, Tornillo L, Terracciano L, Ng CKY, Piscuoglio S, von Flüe M, Spagnoli G, Eppenberger-Castori S, Iezzi G, Drosner RA. Infiltration by IL22-Producing T Cells Promotes Neutrophil Recruitment and Predicts Favorable Clinical Outcome in Human Colorectal Cancer. *Cancer Immunol Res.* (2020) Nov;8(11):1452-1462. doi: 10.1158/2326-6066.CIR-19-0934. Epub 2020 Aug 24. PMID: 32839156

18. Pacifici F, Della-Morte D, Piermarini F, Arriga R, Scioli MG, Capuani B, Pastore D, Coppola A, Rea S, Donadel G, Andreadi A, Abete P, **Sconocchia G**, Bellia A, Orlandi A, Lauro D. Prdx6 Plays a Main Role in the Crosstalk Between Aging and Metabolic Sarcopenia. *Antioxidants (Basel).* (2020) Apr 17;9(4):329. doi: 10.3390/antiox9040329. PMID: 32316601

19. Aureli A, Canossi A, Del Beato T, Buonomo O, Rossi P, Roselli M, Papola F, Marziani B, **Sconocchia G**. Breast Cancer Is Associated with Increased HLA-DRB1*11:01 and HLA-DRB1*10:01 Allele Frequency in a Population of Patients from Central Italy. *Immunol Invest.* (2020) Jul;49(5):489-497. doi: 10.1080/08820139.2020.1737539. Epub 2020 Mar 18. PMID: 32183601

20. Haak F, Obrecht I, Tosti N, Weixler B, Mechera R, Däster S, von Strauss M, Delko T, Spagnoli GC, Terracciano L, **Sconocchia G**, von Flüe M, Kraljević M, Drosner RA. Tumor Infiltration by OX40+ Cells Enhances the Prognostic Significance of CD16+ Cell Infiltration in Colorectal Cancer. *Cancer Control.* (2020) Dec;27(1):1073274820903383. doi: 10.1177/1073274820903383. PMID: 32107932

21. Arriga R, Pacifici F, Capuani B, Coppola A, Orlandi A, Scioli MG, Pastore D, Andreadi A, Sbraccia P, Tesaro M, Daniele ND, **Sconocchia G**, Donadel G, Bellia A, Della-Morte D, Lauro D. Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism. *Oxid Med Cell Longev* (2019) Dec 19;2019:9685607. doi: 10.1155/2019/9685607. eCollection 2019

22. Arriga R, Caratelli S, Lanzilli G, Ottaviani A, Cenciarelli C, Sconocchia T, Spagnoli GC, Iezzi G, Roselli M, Lauro D, Dotti G, Ferrone S, **Sconocchia G**. (2019) CD16-158-Valine Chimeric Receptor T Cells Overcome the Resistance of KRAS-mutated Colorectal Carcinoma Cells to Cetuximab-(pre-print) *Int.J.Cancer*, 146:236-247

23. Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G., Pastore D., Cenciarelli C., Venditti A., Del Principe M.I., Lauro D., Landoni E., Hongwei D.⁵, Savoldo B, Ferrone S, Dotti G., Sconocchia G. Elimination of EGFR-Overexpressing Cancer Cells by CD32 Chimeric Receptor T Cells in Combination with Cetuximab or Panitumumab (2020). *Int.J.Cancer*

24. Del Principe M.I.; Buccisano F.; Soddu S.; Maurillo L.; Cefalo M.; Piciocchi A.; Consalvo M.I.; Paterno G.; Sarlo C.; De Bellis E.; Zizzari A.; De Angelis G.; Fraboni D.; Divona M.; Voso M.T.; **Sconocchia G.**; Del Poeta G.; Lo-Coco F.; Arcese W.; Amadori S.; Venditti A. (2018) Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. *Seminars in Hematology* 2018 DOI: 10.1053/j.seminhematol.2018.02.006

25. Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D, Venditti A, Del principe M, Buccisano F, Maurillo L, Ferrone S, **Sconocchia G** (2017). Fc chimeric receptor engineered T cells: methodology, advantages, limitations and clinical relevance. *FRONTIERS IN IMMUNOLOGY*, vol. 8, ISSN: 1664-3224, doi: 10.3389/fimmu.2017.00457

26. Buccisano, F, Maurillo, L, Piciocchi, A, Del Principe, M.I, Picardi, A, Cerretti, R, Cudillo, L, De Angelis, G, Sarlo, C, Cefalo, M, Ditto, C, Di Veroli, A Mariotti, B, Nasso D, De Bellis, E, Del Poeta, G, Voso, M.T, **Sconocchia G**, Lo Coco F, Arcese W, Amadori S, Venditti A (2017). Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. *BONE MARROW TRANSPLANTATION*, vol. 52, p. 473-475, ISSN: 0268-3369

27. Del Principe, MI, Sarmati, L, Cefalo, M, Fontana, C, De Santis, G, Buccisano, F, Maurillo, L, De Bellis, E, Postorino M, **Sconocchia G**, Del Poeta G, Sanguinetti M, Amadori S, Pagano L, Venditti A (2016). A cluster of *Geotrichum clavatum* (*Saprochaete clavata*) infection in haematological patients: a first Italian report and review of literature. *MYCOSES*, vol. 59, p. 594-601, ISSN: 0933-7407

28. Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, **Sconocchia G** (2016). Enhancement of anti-leukemia activity of Nk cells in vitro and in vivo by inhibition of leukemia cell-induced Nk cell damage. *ONCOTARGET*, vol. 12, p. 2070-2079, ISSN: 1949-2553

29. Del Principe, MI, Buccisano, F, Maurillo L, **Sconocchia G**, Cefalo M, Consalvo MI, Sarlo C, Conti C, De Santis G, de Bellis E, di Veroli A, Palomba P, Attrotto C, Zizzari A, Paterno G, Voso, MT, Del Poeta G, Lo-Coco F Arcese W, Amadori S, Venditti A (2016). Minimal residual disease in acute myeloid leukemia of adults: Determination, prognostic impact and clinical applications. *MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES*, vol. 8, e2016052, ISSN: 2035-3006

30. Canossi A, Aureli A, Del Beato T, Rossi P, Franceschilli L, De Santis F, Sileri P, Di Lorenzo N, Buonomo O, Lauro D, Venditti A, **Sconocchia G** (2016). Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage. *JOURNAL OF TRANSLATIONAL MEDICINE*, vol. 14, ISSN: 1479-5876, doi: 10.1186/s12967-016-1001-y

31. Pastore D, Della-Morte D, Coppola A, Capuani B, Lombardo MF, Pacifici F, Ferrelli F,

- Arriga R, Mammi C, Federici M, Bellia A, Di Daniele N, Tesauro M, Donadel G, Noto D, Sbraccia P, **Sconocchia G**, Lauro D (2016). SGK-1 protects kidney cells against apoptosis induced by ceramide and TNF- α . *CELL DEATH & DISEASE*, vol. 6, ISSN: 2041-4889, doi: 10.1038/cddis.2015.232.
- Basello K, Pacifici F, Capuani B, Pastore D, Lombardo M, Ferrelli F, Coppola A, Donadel G, Arriga R, **Sconocchia G**, Bellia A, Rogliani P, Federici M, Sbraccia P, Lauro D, Della-Morte D. (2016). Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial Senescence by Directly Interacting with hTERT. *REJUVENATION RESEARCH*, vol. 19, p. 79-89, ISSN: 1549-1684
32. D'aloia MM, Caratelli S, Palumbo C, Battella S, Arriga R, Lauro D, Palmieri G, **Sconocchia G (last CO-AUTHOR)**, Alimandi M (2016). T lymphocytes engineered to express a CD16-Chimeric Antigen Receptor. *CYTOTHERAPY*, vol. 18, p. 278-290, ISSN: 1465-3249, doi: 10.1016/j. cyt2015.10.014
33. Däster S, Eppenberger-Castori S, Hirt C, Soysal SD, Delko T, Nebiker CA, Weixler B, Amicarella F, Iezzi G, Governa V, Padovan E, Mele V, **Sconocchia G**, Heberer M, Terracciano L, Kettelhack C, Oertli D, Spagnoli GC, von Holzen U, Tornillo L, Droeser RA. (2015). Absence of myeloperoxidase and CD8 positive cells in colorectal cancer infiltrates identifies patients with severe prognosis. *ONCOIMMUNOLOGY*, vol. 4, ISSN: 2162-4011, doi: 10.1080/2162402X.2015.1050574
34. Del Principe MI, **Sconocchia G**, Buccisano F, Cefalo M, Di Veroli A, De Santis G, Nasso D, Maurillo L, Anemona L, Postorino M, Del Poeta G, Amadori S, Venditti A. (2015). Extensive toxic epidermal necrolysis following brentuximab vedotin administration. *ANNALS OF HEMATOLOGY*, vol. 94, p. 355-356, ISSN: 0939-5555, doi: 10.1007/s00277-014-2148-3
35. Aureli A, Canossi A, Del Beato T, Franceschilli L, Buonomo O, Papola F, De Sanctis F, Lanzilli G, Sileri P, Coppola A, Caratelli S, Arriga R, Orlandi A, Lauro D, Rossi P, **Sconocchia G** (2015). HLA-DRB1*13:01 allele in the genetic susceptibility to colorectal carcinoma. *INTERNATIONAL JOURNAL OF CANCER*, vol. 136, p. 2464-2468, ISSN: 0020-7136, doi: 10.1002/ijc.29285
36. Capuani B, Della-Morte D, Donadel G, Caratelli S, Bova L, Pastore D, De Canio M, D'Aguanno S, Coppola A, Pacifici F, Arriga R, Bellia A, Ferrelli F, Tesauro M, Federici M, Neri A, Bernardini S, Sbraccia P, Di Daniele N, **Sconocchia G**, Orlandi A, Urbani A, Lauro D. (2015). Liver protein profiles in insulin receptor-knockout mice reveal novel molecules involved in the diabetes pathophysiology. *AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOLISM*, vol. 308, p. 744-755, ISSN: 0193-1849, doi: 10.1152/ajpendo.00447.2014
37. Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Sarlo C, Di Veroli A, Panetta P, Irno-Consalvo M, Nasso D, Ditto C, Refrigeri M, De Angelis G, Cerretti R, Arcese W, **Sconocchia G**, Lo-Coco F, Amadori S, Venditti A. (2015). Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. *AMERICAN JOURNAL OF HEMATOLOGY*, vol. 90, p. 125-131, ISSN: 0361-8609, doi: 10.1002/ajh.23893
38. Buccisano, F. Maurillo, L., Piciocchi, A., Del Principe, M.I., Sarlo, C., Cefalo, M., Ditto, C., Di Veroli, A., De Santis, G., Irno Consalvo, M., Fraboni, D., Panetta, P., Palomba, P., Attrotto, C., Del Poeta, G., **Sconocchia G**, Lo-Coco, F., Amadori, S., Venditti, A. (2015). Minimal residual disease negativity in elderly patients with acute
- 39.

- myeloid leukemia may indicate different postremission strategies than in younger patients. *ANNALS OF HEMATOLOGY*, vol. 94, p. 1319-1326, ISSN: 0939-5555, doi: 10.1007/s00277-015-2364-5
40. Coppola A, Arriga R, Lauro D, Del Principe MI, Buccisano F, Maurillo L, Palomba P, Venditti A, **Sconocchia G** (2015). NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma. *FRONTIERS IN MEDICINE*, vol. 2, ISSN: 2296-858X, doi: 10.3389/fmed.2015.00033
41. Coppola A, Arriga R, Lauro D, Del Principe MI, Buccisano F, Maurillo L, Palomba P, Venditti A, **Sconocchia G** (2015). NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma. *FRONTIERS IN MEDICINE*, ISSN: 2296-858X, doi: 10.3389/fmed.2015.00033
42. Benvenuto M, Sileri P, Rossi P, Masuelli L, Fantini M, Nanni M, Franceschilli L, **Sconocchia G**, Lanzilli G, Arriga R, Faggioni G, Lista F, Orlandi A, Manzari V, Gaspari AL, Modesti A, Bei R (2015). Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients. *JOURNAL OF TRANSLATIONAL MEDICINE*, vol. 13, ISSN: 1479-5876, doi: 10.1186/s12967-015-0455-7
43. Weixler B, Cremonesi E, Sorge R, Muraro MG, Delko T, Nebiker CA, Däster S, Governa V, Amicarella F, Soysal SD, Kettelhack C, von Holzen UW, Eppenberger-Castori S, Spagnoli GC, Oertli D, Iezzi G, Terracciano L, Tornillo L, **Sconocchia G (LAST COAUTHOR)**, Droeser RA. (2015). OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer. *ONCOTARGET*, vol. 6, p. 37588-37599, ISSN: 1949-2553, doi: 10.18632/oncotarget.5940
44. Ferrelli F, Pastore D, Capuani B, Lombardo MF, Blot-Chabaud M, Coppola A, Basello K, Galli A, Donadel G, Romano M, Caratelli S, Pacifici F, Arriga R, Di Daniele N, Sbraccia P, **Sconocchia G**, Bellia A, Tesauro M, Federici M, Della-Morte D, Lauro D. (2015). Serum glucocorticoid inducible kinase (SGK)-1 protects endothelial cells against oxidative stress and apoptosis induced by hyperglycaemia. *ACTA DIABETOLOGICA*, vol. 52, p. 55-64, ISSN: 0940-5429, doi: 10.1007/s00592-014-0600-4
45. Del Principe MI, Maurillo L, Buccisano F, **Sconocchia G**, Cefalo M, De Santis G, Di Veroli A, Ditto C, Nasso D, Postorino M, Refrigeri M, Attrotto C, Del Poeta G, Lo-Coco F, Amadori S, Venditti A. (2014). Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. *MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES*, vol. 6, ISSN: 2035-3006, doi: 10.4084/MJHID.2014.075
46. Nebiker CA, Han J, Eppenberger-Castori S, Iezzi G, Hirt C, Amicarella F, Cremonesi E, Huber X, Padovan E, Angrisani B, Droeser RA, Rosso R, Bolli M, Oertli D, von Holzen U, Adamina M, Muraro MG, Mengus C, Zajac P, **Sconocchia G**, Zuber M, Tornillo L, Terracciano L, Spagnoli GC (2014). GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer. *CLINICAL CANCER RESEARCH*, vol. 20, p. 3094-3106, ISSN: 1078-0432, doi: 10.1158/1078-0432.CCR-13-2774
47. **Sconocchia G**, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Droeser R, Rossi P, Attanasio A, Ferrone S, Terracciano L. (2014). HLA

- class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. *NEOPLASIA*, vol. 16, p. 31-42, ISSN: 1522-8002
48. Däster S, Eppenberger-Castori S, Hirt C, Zlobec I, Delko T, Nebiker CA, Soysal SD, Amicarella F, Iezzi G, **Sconocchia G**, Heberer M, Lugli A, Spagnoli GC, Kettelhack C, Terracciano L, Oertli D, von Holzen U, Tornillo L, Droeser RA. (2014). High frequency of CD8 positive lymphocyte infiltration correlates with lack of lymph node involvement in early rectal cancer. *DISEASE MARKERS*, ISSN: 0278-0240, doi: 10.1155/2014/792183
49. Del Principe MI, Buccisano F, Cefalo M, Maurillo L, Di Caprio L, Di Piazza F, Sarlo C, De Angelis G, Irno Consalvo M, Fraboni D, De Santis G, Ditto C, Postorino M, **Sconocchia G**, Del Poeta G, Amadori S, Venditti A. (2014). High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma. *ANNALS OF HEMATOLOGY*, vol. 93, p. 1509-1513, ISSN: 0939-5555, doi: 10.1007/s00277-014-2080-6
50. **Sconocchia G**, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D, Iezzi G, Terracciano L, Ferrone S. (2014). NK cells and T cells cooperate during the clinical course of colorectal cancer. *ONCOIMMUNOLOGY*, vol. 3, p. 952197-1-952197-6, ISSN: 2162-4011, doi: 10.4161/21624011.2014.952197
51. Pacifici F, Arriga R, Sorice GP, Capuani B, Scioli MG, Pastore D, Donadel G, Bellia A, Caratelli S, Coppola A, Ferrelli F, Federici M, **Sconocchia G**, Tesauro M, Sbraccia P, Della-Morte D, Giaccari A, Orlandi A, Lauro D. (2014). Peroxiredoxin 6, a novel player in the pathogenesis of diabetes. *DIABETES*, vol. 63, p. 3210-3220, ISSN: 0012-1797, doi: 10.2337/db14-0144
52. Bei R, Romano M, Caputo MP, **Sconocchia G**, Capuani B, Coppola A, Nucci C, Pastore D, Bellia A, Mancino R, Andreadi K, Cerilli M, Bertoli A, Modesti A, Lauro D (2013). A survey of autoantibodies to self-antigens in graves' disease patients with thyroid-associated ophthalmopathy. *EUROPEAN JOURNAL OF INFLAMMATION*, vol. 11, p. 539-546, ISSN: 1721-727X
53. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, **Sconocchia G**, Oertli D, Spagnoli GC, Tornillo L. (2013). Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. *EUROPEAN JOURNAL OF CANCER*, vol. 49, p. 2233-2242, ISSN: 0959-8049, doi: 10.1016/j.ejca.2013.02.015
54. Hirt C, Eppenberger-Castori S, **Sconocchia G**, Iezzi, G, Tornillo L, Terracciano L, Spagnoli GC, Droeser RA (2013). Colorectal carcinoma infiltration by myeloperoxidase-expressing neutrophil granulocytes is associated with favorable prognosis. *ONCOIMMUNOLOGY*, vol. 2, ISSN: 2162-4011, doi: 10.4161/onci.25990
55. Droeser RA, Hirt C, Eppenberger-Castori S, Zlobec I, Viehl CT, Frey DM, Nebiker CA, Rosso R, Zuber M, Amicarella F, Iezzi G, **Sconocchia G**, Heberer M, Lugli A, Tornillo L, Oertli D, Terracciano L, Spagnoli GC (2013). High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. *PLOS ONE*, vol. 8, ISSN: 1932-6203, doi: 10.1371/journal.pone.0064814
56. **Sconocchia G**, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC (2012).

- Melanoma cells inhibit NK cell functions. *CANCER RESEARCH*, vol. 72, p. 5428-5429, ISSN: 0008-5472, doi: DOI:10.1158/0008-5472
57. **Sconocchia G** (2012). Innate inflammation and cancer: The colorectal carcinoma paradox. *ENDOCRINOLOGY & METABOLIC SYNDROME*, vol. 1, p. 1-2, ISSN: 2161-1017, doi: DOI:http://dx.doi.org/10.4172/2161-1017.1000e105
58. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, **Sconocchia G**, Lo-Coco F, Arcese W, Amadori S, Venditti A (2012). Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. *BLOOD*, vol. 119, p. 332-341, ISSN: 0006-4971, doi: 10.1182/blood-2011-08-363291
59. **Sconocchia G**, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Drosner R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC (2011). Tumor infiltration by Fc gamma RIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. *INTERNATIONAL JOURNAL OF CANCER*, vol. 128, p. 2663-2672, ISSN: 0020-7136, doi: 10.1002/ijc.25609
60. Gravante G, Ong SL, Metcalfe MS, Sorge R, **Sconocchia G**, Orlando G, Lloyd DM, Dennison AR (2009). Cytokine response to ischemia/reperfusion injury in an ex vivo perfused porcine liver model. *TRANSPLANTATION PROCEEDINGS*, vol. 41, p. 1107-1112, ISSN: 0041-1345, doi: 10.1016/j.transproceed.2009.02.054.
61. **Sconocchia G**, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L (2009). Defective Infiltration of Natural Killer Cells in MICA/B-Positive Renal Cell Carcinoma Involves beta (2)-Integrin-Mediated Interaction. *NEOPLASIA*, vol. 11, p. 662-671, ISSN: 1522-8002, doi: 10.1593/neo.09296
62. Gravante G, **Sconocchia G**, Ong SL, Dennison AR, Lloyd DM (2009). Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. *LIVER INTERNATIONAL*, vol. 29, p. 18-24, ISSN: 1478-3223, doi: 10.1111/j.1478-3231.200801915.x
63. Wongsena W, **Sconocchia G**, Cho HS, Chang CC, Wang X, Klumkrathok K, Ferrone S, Leelayuwat C (2008). Production and characterization of monoclonal antibodies against major histocompatibility complex class I chain-related gene A. *TISSUE ANTIGENS*, vol. 72, p. 431-440, ISSN: 0001-2815, doi: 10.1111/j.1399-0039.2008.01118.x
64. Gravante G, Delogu D, **Sconocchia G** (2007). "Systemic apoptotic response" after thermal burns. *APOPTOSIS*, vol. 12, p. 259-270, ISSN: 1360-8185, doi: 10.1007/s10495-006-0621-8
65. **Sconocchia G**, Del Principe D, Barrett AJ (2007). CD16(low/negative) tumor-infiltrating lymphocyte: Lymphoid or myeloid in origin? *CLINICAL CANCER RESEARCH*, vol. 13, p. 1620, ISSN: 1078-0432, doi: 10.1158/1078-0432.CCR-06-2247
66. Rezvani K, Price DA, Brenchley JM, Kilical Y, Gostick E, **Sconocchia G**, Hansmann K, Kurlander R, Douek DC, Barrett AJ (2007). Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. *CYTOTHERAPY*, vol. 9, p. 245-251, ISSN: 1465-3249, doi: 10.1080/14653240701218524
67. Gravante G, Filingeri V, Delogu D, Santeusano G, Palmieri MB, Esposito G, Montone

- A, **Sconocchia G** (2006). Apoptotic cell death in deep partial thickness burns by coexpression analysis of TUNEL and Fas. *SURGERY*, vol. 139, p. 854-855, ISSN: 0039-6060, doi: 10.1016/j.surg.2006.01.024
68. Gravante G, Palmieri MB, Esposito G, Filingeri V, Delogu D, Santeusano G, **Sconocchia G**, Montone A (2006). Dermal apoptosis is not influenced by the severity of clinical conditions in burned patients. *EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES*, vol. 10, p. 207-209, ISSN: 1128-3602
69. Gravante G, Esposito G, Delogu D, Montone A, **Sconocchia G** (2006). More than two different bacterial species isolated from blood of toxic epidermal necrolysis patients significantly increase mortality. *BURNS*, vol. 32, p. 793-794, ISSN: 0305-4179, doi: 10.1016/j.burns.2006.03.026
- 70.. **Sconocchia G**, del Principe D, Barrett AJ (2006). Non-classical antileukemia activity of early recovering NK cells after induction chemotherapy and HLA-identical stem cell transplantation in myeloid leukemias. *LEUKEMIA*, vol. 20, p. 1632-1633, ISSN: 0887-6924, doi: 10.1038/sj.leu.2404300
71. Li J, Melenhorst J, Hensel N, Rezvani K, **Sconocchia G**, Kilical Y, Hou J, Curfman B, Major E, Barrett AJ (2006). T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. *JOURNAL OF GENERAL VIROLOGY*, vol. 87, p. 2951-2960, ISSN: 0022-1317, doi: 10.1099/vir.0.82094-0
72. Gravante G, Esposito G, Marianetti M, Delogu D, Montone A, **Sconocchia G** (2006). Toxic epidermal necrolysis in patients with malignancies. *ANNALS OF ONCOLOGY*, vol. 17, p. 1601, ISSN: 0923-7534, doi: 10.1093/annonc/mdl089
73. Ferrone S, **Sconocchia G** (2005). A clinically relevant mouse model of human multiple myeloma? *BLOOD*, vol. 106, p. 388-389, ISSN: 0006-4971, doi: 10.1182/blood-2005-04-1676
74. **Sconocchia G**, Provenzano M, Rezvani K, Li JM, Melenhorst J, Hensel N, Barrett AJ (2005). CD34+cells cultured in stem cell factor and interleukin-2 generate CD56+cells with antiproliferative effects on tumor cell lines. *JOURNAL OF TRANSLATIONAL MEDICINE*, vol. 3, ISSN: 1479-5876, doi: 10.1186/1479-5876-3-15
75. Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, **Sconocchia G**, Rezvani K, Price DA, Hensel NF, Douek DC, Barrett AJ (2005). In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. *CLINICAL CANCER RESEARCH*, vol. 11, p. 4495-4503, ISSN: 1078-0432, doi: 10.1158/1078-0432.CCR-04-2363
76. **Sconocchia G**, Keyvanfar K, El Ouriaghli F, Grube M, Rezvani K, Fujiwara H, McCoy JP, Hensel N, Barrett AJ (2005). Phenotype and function of a CD56+peripheral blood monocyte. *LEUKEMIA*, vol. 19, p. 69-76, ISSN: 0887-6924, doi: 10.1038/sj.leu.2403550
77. **Sconocchia G**, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li JM, Ferrone S, Barrett AJ (2005). The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. *BLOOD*, vol. 106, p. 3666-3672, ISSN: 0006-4971, doi: 10.1182/blood-2005-02-0479
78. Grube M, Rezvani K, Wiestner A, Fujiwara H, **Sconocchia G**, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA (2004). Autoreactive, Cytotoxic T

Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies. *CLINICAL CANCER RESEARCH*, vol. 10, p. 1047-1056, ISSN: 1078-0432, doi: 10.1158/1078-0432.CCR-03-0075

79. **Sconocchia G**, Fujiwara H, Rezvani K, Keyvanfar K, El Ouriaghli F, Grube M, Melenhorst J, Hensel N, Barrett AJ (2004). G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte. *JOURNAL OF LEUKOCYTE BIOLOGY*, vol. 76, p. 1214-1219, ISSN: 0741-5400, doi: 10.1189/jlb.0504278
80. Fujiwara H, El Ouriaghli F, Grube M, Price DA, Rezvani K, Gostick E, **Sconocchia G**, Melenhorst J, Hensel N, Douek DC, Barrett AJ (2004). Identification and in vitro expansion of CD4+ and CD8 + T cells specific for human neutrophil elastase. *BLOOD*, vol. 103, p. 3076-3083, ISSN: 0006-4971, doi: 10.1182/blood-2003-07-2424
81. El Ouriaghli F, Sioand E, Mainwaring L, Fujiwara H, Keyvanfar K, Melenhorst JJ, Rezvani K, **Sconocchia G**, Solomon S, Hensel N, Barrett AJ (2003). Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. *BLOOD*, vol. 102, p. 3786-3792, ISSN: 0006-4971
82. Rezvani K, Grube M, Brenchley JM, **Sconocchia G**, Fujiwara H, Price DA, Gostick E, Yamada K, Melenhorst J, Childs R, Hensel N, Douek DC, Barrett AJ (2003). Functional leukemia-associated antigen-specific memory CD8(+) T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. *BLOOD*, vol. 102, p. 2892-2900, ISSN: 0006-4971, doi: 10.1182/blood-2003-01-0150
83. El Ouriaghli F, Fujiwara H, Melenhorst JJ, **Sconocchia G**, Hensel N, Barrett AJ (2003). Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. *BLOOD*, vol. 101, p. 1752-1758, ISSN: 0006-4971, doi: 10.1182/blood-2002-06-1734
84. Fujiwara H, **Sconocchia G**, Melenhorst J, Eniafe R, Nakamura R, Hensel N, Barrett AJ (2003). Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs. *BONE MARROW TRANSPLANTATION*, vol. 32, p. 371-378, ISSN: 0268-3369, doi: 10.1038/sj.bmt.1704142
85. Lande R, Urbani F, Di Carlo B, **Sconocchia G**, Deaglio S, Funaro A, Malavasi F, Ausiello CM (2002). CD38 ligation plays a direct role in the induction of IL-1 beta, IL-6, and IL-10 secretion in resting human monocytes. *CELLULAR IMMUNOLOGY*, vol. 220, p. 30-38, ISSN: 0008-8749, doi: 10.1016/S0008-8749(03)00025-X
86. **Sconocchia G**, Campagnano L, Adorno D, Iacona A, Cococetta NY, Boffo V, Amadori S, Casciani CU (2001). CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. *BLOOD*, vol. 97, p. 3621-3627, ISSN: 0006-4971, doi: 10.1182/ blood. V97.11.3621
87. **Sconocchia G**, Campagnano L, Cococetta N, Iorio B, Ferdinandi E, Del Principe I, Adorno D, Amadori S, Casciani C.U. (2001). Subcutaneous administration of interleukin 2 triggers FcgammaRI expression on human peripheral polymorphonuclear cells in solid malignancies. *JOURNAL OF IMMUNOTHERAPY*, vol. 24, ISSN: 1524-9557

88. **Sconocchia G**, Titus JA, Mazzoni A, Visintin A, Pericle F, Hicks SW, Malavasi F, Segal DM (1999). CD38 triggers cytotoxic responses in activated human natural killer cells. *BLOOD*, vol. 94, p. 3864-3871, ISSN: 0006-4971
89. Pericle F, Pinto LA, Hicks S, Kirken RA, **Sconocchia G**, Rusnak J, Dolan MJ, Shearer GM, Segal DM (1998). Cutting edge: HIV-1 infection induces a selective reduction in STAT5 protein expression. *JOURNAL OF IMMUNOLOGY*, vol. 160, p. 28-31, ISSN: 0022-1767
90. Pericle F, Kirken RA, Bronte V, **Sconocchia G**, DaSilva L, Segal DM (1997). Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. *JOURNAL OF IMMUNOLOGY*, vol. 159, p. 2580-2585, ISSN: 0022-1767
91. **Sconocchia G**, Titus JA, Segal DM (1997). Signaling pathways regulating CD44-dependent cytotoxicity in natural killer cells. *BLOOD*, vol. 90, p. 716-725, ISSN: 0006-4971
92. Wickham TJ, Lee GM, Titus JA, **Sconocchia G**, Bakacs T, Kovesdi I, Segal DM (1997). Targeted adenovirus-mediated gene delivery to T cells via CD3. *JOURNAL OF VIROLOGY*, vol. 71, p. 7663-7669, ISSN: 0022-538X
93. **Sconocchia G**, Titus IA, Pericle F, Segal PM (1996). A tyrosine phosphorylated protein may link CD44 to NK cytotoxicity. *FASEB JOURNAL*, vol. 10, ISSN: 0892-6638
94. Pericle F, **Sconocchia G**, Titus JA, Segal DM (1996). CD44 is a cytotoxic triggering molecule on human polymorphonuclear cells. *JOURNAL OF IMMUNOLOGY*, vol. 157, p. 4657-4663, ISSN: 0022-1767
95. Pericle F, **Sconocchia G**, Segal PM (1996). Hyaluronan binding to CD44 on human neutrophils induces PMN tumoricidal activity. *FASEB JOURNAL*, vol. 10, ISSN: 0892-6638
96. Segal DM, **Sconocchia G**, Titus JA, Jost CR, Kurucz I. (1995). Alternative triggering molecules and single chain bispecific antibodies. *JOURNAL OF HEMATOTHERAPY*, vol. 4, p. 377-382, ISSN: 1061-6128
97. Filingeri V, Rosati R, **Sconocchia G**, Pisani A, Vennarecci G, Anselmo A, Pepe N, Barletta N, Casciani CU (1995). Synergism between cyclosporin A and gangliosides in antirejection therapy: An experimental model in vivo. *MINERVA CHIRURGICA*, vol. 50, p. 275-278, ISSN: 0026-4733
98. **Sconocchia g**, Titus JA, Segal D.M. (1994). CD44 is a cytotoxic triggering molecule in human peripheral-blood nk cells. *Journal of immunology*, vol. 153, p. 5473-5481, issn: 0022-1767
99. Ausiello CM, Adorno D, Grana G, Urbani F, Spagnoli GC, **Sconocchia G**, Cococetta N, Casciani CU (1993). Inhibitory effects of gangliosides and cyclosporine on lymphocyte activation: Analysis of cytokine gene mRNA transcripts. *TRANSPLANTATION PROCEEDINGS*, vol. 25, p. 2315-2316, ISSN: 0041-1345
100. **Sconocchia G**, Ausiello CM, Spagnoli GC, Sciortino G, Filinger V, Giudiceandrea F, Cervelli V, Adorno D, Casciani CU (1992). Gangliosides potentiate the immunosuppressive effects of cyclosporin A in rat skin allografts. *TRANSPLANT INTERNATIONAL*, vol. 5, p. 544-546, ISSN: 0934-0874
101. Spagnoli GC, Ausiello CM, **Sconocchia G**, Adorno D, Casciani CU (1991). Gangliosides potentiate cyclosporine A-induced suppression of allospecific immune responses. *TRANSPLANTATION PROCEEDINGS*, vol. 23, p. 342-345, ISSN: 0041-

1345

102. Ausiello CM, Spagnoli GC, **Sconocchia G**, Pisani F, Adorno D, Casciani CU (1991). Low responsiveness to Candida antigens in kidney transplant recipients. MICROBIOLOGICA, vol. 14, p. 325-332, ISSN: 0391-5352

CAPITOLI DI LIBRI

98. D. Segal, T. Bakacs, C. Jost, I. Kurucz, **G. Sconocchia**, and J.A. Titus: T cell-targeted cytotoxicity: Bispecific Antibodies. Springer-Verlag, Heidelberg, Germany. 1995
99. Segal, D.M., Vance, B.A., and **Sconocchia, G.** Bispecific Antibodies, in Antibodies in diagnosis and therapy: Technologies, mechanisms and clinical data, S. Matzku, and R.A. Stahel, eds. Harwood Academic Publishers, Amsterdam, 1999, pp 49-80

ORAL PRESENTATIONS

- 99b. **G. Sconocchia**, J. Titus and D.M. Segal: CD44 is a triggering molecule on Natural Killer Cells: Experimental Biology 1994, Anaheim, 24-28 April, California.
100. **G. Sconocchia**: Multiple triggering molecules on NK cells. Bispecific Antibodies International Meeting. 1997 Volendam, The Netherlands 14-18 June
101. **G. Sconocchia**: Retargeting of lymphoid and myeloid cells by bispecific antibodies in: Gli anticorpi monoclonali in terapia oncologica: mito o realta'. March, 1998, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano.
- 102 **G. Sconocchia**, L. Campagnano, D. Adorno, A. Iacona, S. Amadori, and C.U.Casciani: CD44 ligation on human polymorphonuclear cells induces interleukin-6 production. 28th World Congress of Hematology, Toronto (Canada), August 26-30, 2000
103. **G. Sconocchia**: Antileukemia activity of LAK cells on HLA-matched chronic myelogenous leukaemia. DKBW guest seminar. Department of Research. University of Basel, Basel, Switzerland
104. **G. Sconocchia**: Late-Breaking news: MICA expression in metastatic renal cell carcinoma is not accompanied by NK cell infiltration but is associated with CD16 positive macrophages. 4th International Symposium on the clinical use of the cellular products: Cellular Therapy 2007, Regensburg, Germany.
105. **G. Sconocchia**: Scrutiny of colorectal carcinoma microenvironment reveals novel, biological prognostic factors: The role of Fc-gamma-RIII and HLA-DR. 17 International Congress in Advances in Oncology, Rodi, October 6-9, 2011
106. **G. Sconocchia**: Autoimmunity of diabetes. Medical Summar School, University of Rome

Tor Vergata-ERASMUS, Rome July24-August 2, 2012

107. G.Sconocchia: Analisi citometrica e test funzionali immunologici. Corso teorico pratico di citofluorimetria in ambito ematologico. Roma 7-8 luglio, 2014

108. G.Sconocchia: Avanzamenti della citometria in applicazioni cliniche e di ricerca. XXXII conferenza nazionale di citometria della Società Italiana di Citometria (CIG), Urbino 23-26 settembre, 2014

109. Venditti A, Buccisano F, Maurillo L, Del Principe MI, Coppola A, Palomba P, Aureli A, Arriga R, Bellarosa D, Bressan A, Wilson K, Manzini S, Capriati A, Simonelli C, Binaschi M, Amadori S, **Sconocchia G.** Preclinical Characterization of MEN1112/OBT357, a Novel Anti-Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Ex Vivo Translational Assay. 57° ASH Meeting, Orlando, 5-8 December 2015

110.G. Sconocchia: Invited speaker: T-Cells Engineered with FC-Gamma Chimeric Receptors Generate Effector Cells with NK-Like Cytotoxicity. Cell Culture Days, Uni Klinikum, GRAZ (AT), October 4-5, 2021.

Roma 20/01/2021

Firma